Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development

Katherine S Hansen; C. Khanna

doi:10.1016/j.ejca.2003.11.031

Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development

Katherine S Hansen, C. Khanna

Research output: Contribution to journal › Article

162 Scopus citations

Abstract

The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.

Original language	English (US)
Pages (from-to)	858-880
Number of pages	23
Journal	European Journal of Cancer
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ejca.2003.11.031
State	Published - Apr 2004
Externally published	Yes

Keywords

Cancer
Canine
Comparative
GEM
Mouse
Spontaneous
Transgenic

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.ejca.2003.11.031

Fingerprint Dive into the research topics of 'Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development'. Together they form a unique fingerprint.

Cite this

Hansen, K. S., & Khanna, C. (2004). Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development. European Journal of Cancer, 40(6), 858-880. https://doi.org/10.1016/j.ejca.2003.11.031

@article{d51f1ec615e74ae096acd8e9f6ffa2e8,

title = "Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development",

abstract = "The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.",

keywords = "Cancer, Canine, Comparative, GEM, Mouse, Spontaneous, Transgenic",

author = "Hansen, {Katherine S} and C. Khanna",

year = "2004",

month = apr,

doi = "10.1016/j.ejca.2003.11.031",

language = "English (US)",

volume = "40",

pages = "858--880",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Spontaneous and genetically engineered animal models

T2 - Use in preclinical cancer drug development

AU - Hansen, Katherine S

AU - Khanna, C.

PY - 2004/4

Y1 - 2004/4

N2 - The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.

AB - The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.

KW - Cancer

KW - Canine

KW - Comparative

KW - GEM

KW - Mouse

KW - Spontaneous

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=1942518888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942518888&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2003.11.031

DO - 10.1016/j.ejca.2003.11.031

M3 - Article

C2 - 15120042

AN - SCOPUS:1942518888

VL - 40

SP - 858

EP - 880

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -